MapLight Therapeutics, Inc. (MPLT) Stock Statistics & Valuation Metrics

MapLight Therapeutics, Inc. has a market cap or net worth of $1.25B. The enterprise value is -$27.42M.

MapLight Therapeutics, Inc. has 42,610,080 shares outstanding. The number of shares has decreased by -2.65% in one year.

MapLight Therapeutics, Inc.’s return on equity (ROE) is -0.35 and return on invested capital (ROIC) is -36.43%.

The current PE Ratio of MapLight Therapeutics, Inc. is ―. MapLight Therapeutics, Inc.’s PEG ratio is -0.05.

In the last 12 months, MapLight Therapeutics, Inc. had revenue of 0.00 and earned -161.15M in profits. Earnings per share was -3.66.

In the last 12 months, operating cash flow was -163.76M and capital expenditures -497.00K, giving a free cash flow of -164.26M billion.

MapLight Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

MapLight Therapeutics, Inc. upcoming earnings date is May 14, 2026, Before Open (Confirmed).

MapLight Therapeutics, Inc. as a current ratio of 20.01, with Debt / Equity ratio of 1.40%

In the past 12 months, MapLight Therapeutics, Inc. has paid 0.00 in taxes.

MapLight Therapeutics, Inc. EV to EBITDA ratio is -4.35, with an EV/FCF ratio of -5.29.

MapLight Therapeutics, Inc. has $310.11M in cash and marketable securities with $5.59M in debt, giving a net cash position of $304.52M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for MapLight Therapeutics, Inc. is $39.05, which is 11.43% higher than the current price. The consensus rating is Strong Buy